Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
April 25, 2023 - … endpoints. In addition to QALSODY, the company has a pipeline of investigational drugs being evaluated in ALS, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of ALS; the potential of our commercial business and pipeline programs, including QALSODY; and risks and …
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … disease; the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; the potential … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
BIOGEN TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS APRIL 25, 2023
April 11, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Appoints Adam Keeney as Head of Corporate Development
April 4, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
March 29, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … disease; the potential of Biogen's commercial business and pipeline programs, including BIIB080; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
March 22, 2023 - … sensitive clinical endpoints. Today, the company has a pipeline of investigational drugs being evaluated in ALS, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of ALS; the potential of our commercial business and pipeline programs, including tofersen; and risks and …
Biogen to Participate in the Stifel 2023 CNS Days
March 17, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of, and expectations for, and our commercial business and pipeline programs; These forward-looking statements may be … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
